Prediction Discrepancies for the Evaluation of Nonlinear Mixed-Effects Models
暂无分享,去创建一个
[1] Alan E. Gelfand,et al. Model Determination using sampling-based methods , 1996 .
[2] N H Holford,et al. Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.
[3] L. Ryan,et al. ASSESSING NORMALITY IN RANDOM EFFECTS MODELS , 1989 .
[4] Sylvia Richardson,et al. Markov Chain Monte Carlo in Practice , 1997 .
[5] Ralph B. D'Agostino,et al. Goodness-of-Fit-Techniques , 2020 .
[6] P. McCullagh,et al. Generalized Linear Models , 1972, Predictive Analytics.
[7] L Aarons,et al. Role of modelling and simulation in Phase I drug development. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[8] James M. Robins,et al. Asymptotic Distribution of P Values in Composite Null Models , 2000 .
[9] L B Sheiner,et al. Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.
[10] James M. Robins,et al. Rejoinder to discussion of ``The asymptotic distribution of P-values in composite'' null models. , 2000 .
[11] Walter R. Gilks,et al. Model checking and model improvement , 1995 .
[12] L. Lesko,et al. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.
[13] L Aarons,et al. Software for Population Pharmacokinetics and Pharmacodynamics , 1999, Clinical pharmacokinetics.
[14] M. J. Bayarri,et al. P Values for Composite Null Models , 2000 .
[15] R. Gomeni,et al. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. , 1995, Journal of biopharmaceutical statistics.
[16] J. Q. Smith,et al. 1. Bayesian Statistics 4 , 1993 .
[17] Population Pharmacokinetics. Guidance for Industry Population Pharmacokinetics , 1999 .
[18] E. Vonesh,et al. Linear and Nonlinear Models for the Analysis of Repeated Measurements , 1996 .
[19] Hui C. Kimko,et al. Simulation for Designing Clinical Trials : A Pharmacokinetic-Pharmacodynamic Modeling Perspective , 2002 .
[20] France Mentré,et al. Population Pharmacokinetic Analysis of Mizolastine and Validation from Sparse Data on Patients Using the Nonparametric Maximum Likelihood Method , 2004, Journal of Pharmacokinetics and Biopharmaceutics.
[21] Russell D. Wolfinger,et al. Two Taylor-series approximation methods for nonlinear mixed models , 1997 .
[22] A. Mallet. A maximum likelihood estimation method for random coefficient regression models , 1986 .
[23] L. Sheiner,et al. Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[24] Ene I. Ette,et al. Determination of Model Appropriateness , 2002 .
[25] Michael Evans,et al. Asymptotic Distribution of P Values in Composite Null Models: Comment , 2000 .
[26] Hong Chang,et al. Model Determination Using Predictive Distributions with Implementation via Sampling-Based Methods , 1992 .
[27] Emmanuelle Comets,et al. Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[28] David J. Spiegelhalter,et al. Estimation of population pharmacokinetics using the Gibbs sampler , 1995, Journal of Pharmacokinetics and Biopharmaceutics.
[29] Malcolm Rowland,et al. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2004, Pharmaceutical Research.
[30] L. Skovgaard. NONLINEAR MODELS FOR REPEATED MEASUREMENT DATA. , 1996 .